Doximity, Inc. (NASDAQ:DOCS) Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC trimmed its stake in Doximity, Inc. (NASDAQ:DOCSFree Report) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,548,455 shares of the company’s stock after selling 289,635 shares during the quarter. Doximity makes up 2.0% of ArrowMark Colorado Holdings LLC’s portfolio, making the stock its 8th biggest holding. ArrowMark Colorado Holdings LLC owned approximately 1.91% of Doximity worth $154,606,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DOCS. Farther Finance Advisors LLC grew its holdings in Doximity by 324.2% in the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after purchasing an additional 603 shares during the period. Blue Trust Inc. increased its position in shares of Doximity by 621.4% in the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock worth $37,000 after purchasing an additional 1,193 shares during the last quarter. Quarry LP boosted its holdings in shares of Doximity by 101.2% in the 2nd quarter. Quarry LP now owns 1,616 shares of the company’s stock valued at $45,000 after buying an additional 131,253 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Doximity during the first quarter valued at approximately $46,000. Finally, First Horizon Advisors Inc. increased its position in Doximity by 80.0% in the second quarter. First Horizon Advisors Inc. now owns 1,710 shares of the company’s stock worth $48,000 after buying an additional 760 shares during the period. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Doximity Stock Performance

DOCS opened at $53.00 on Monday. The stock has a 50-day moving average of $45.86 and a 200-day moving average of $36.09. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $61.75. The company has a market cap of $9.89 billion, a PE ratio of 60.92, a price-to-earnings-growth ratio of 4.25 and a beta of 1.30.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. The Goldman Sachs Group began coverage on Doximity in a research note on Friday, November 15th. They issued a “neutral” rating and a $58.00 price target for the company. Evercore ISI increased their price objective on shares of Doximity from $34.00 to $45.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Raymond James restated an “outperform” rating and issued a $65.00 target price (up from $37.00) on shares of Doximity in a research report on Friday, November 8th. Bank of America boosted their price objective on Doximity from $32.00 to $45.00 and gave the stock a “neutral” rating in a research note on Monday, October 7th. Finally, Robert W. Baird lifted their target price on Doximity from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $52.27.

Read Our Latest Analysis on DOCS

Doximity Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Read More

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.